Prime Medicine, Inc. (PRME)
3.55
+0.15
(+4.41%)
USD |
NASDAQ |
May 29, 16:00
3.55
0.00 (0.00%)
After-Hours: 20:00
Prime Medicine Enterprise Value : 620.21M for May 29, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 10.55B |
| Oncolytics Biotech, Inc. | 119.14M |
| Sangamo Therapeutics, Inc. | 81.93M |
| Sarepta Therapeutics, Inc. | 2.270B |
| Anixa Biosciences, Inc. | 75.29M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -49.12M |
| Revenue (Quarterly) | 0.856M |
| Total Expenses (Quarterly) | 49.98M |
| EPS Diluted (Quarterly) | -0.2774 |
| Gross Profit Margin (Quarterly) | -116.8% |
| Profit Margin (Quarterly) | -5.74K% |
| Earnings Yield | -35.35% |
| Normalized Earnings Yield | -35.51 |